ent of BioChemistry and Center in Molecular Toxicology, Vanderbilt University, Nashville, Tennessee

1985 B.S., Summa cum laude, Chemistry and Biology, Murray State University, Murray, Kentucky 
 

Brief Chronology of Employment: 
 

2002-Date  Staff Scientist, Retroviral Molecular Pathogenesis Section, Laboratory of Cancer Prevention, National Cancer Institute, Frederick, Maryland 

2000-2002  BioMedical Scientist and Breast Cancer Research Program Coordinator, Science Applications International Corporation, Department of Defense Congressionally Directed Medical Research Programs, Ft. Detrick, Frederick, Maryland

1996-1999  Biotechnology Training Program Fellow, Gene Regulation Section, Basic Research Laboratory, National Cancer Institute, Frederick, Maryland

1991-1996  Postdoctoral Research Fellow, Gene Regulation Section, Basic Research Laboratory, National Cancer Institute, Frederick, Maryland

1985-1991  Graduate Student, Department of Biochemistry, Vanderbilt University, Nashville,  Tennessee

1994   Cooperative Education Student, National Center for Toxicological Research, Division of Chemistry, Jefferson, Arkansas 
 

Honors and Awards: 
 

1991-1996  Intramural Research Training Award, NIH

1994   Brigid Leventhal Trainee Award, Women in Cancer Research

1985-1989  University Graduate Fellowship, Vanderbilt University

1989   L. S. Hnilica Toxicology Student Lecture, Committee Chairperson

1986-1987  Vanderbilt Biochemistry Student Association, President

1980-1985  Presidential Scholarship, Murray State University

1985   Outstanding Senior Woman, Murray State University

1985   Outstanding American Chemical Society-Approved Area in Chemistry, Murray State University 
 

 
 

Societies: 

      American Association for Cancer Research

      HIV and Cancer Virology Faculty, National Cancer Institute

      Cancer Prevention Faculty, National Cancer Institute

      Staff Scientist and Staff Clinician Organization, National Cancer Institute 
 

 
 

Publications: 
 

1. Thompson, H.C., Jr., Gosnell, A.B., Holder, C.L., Siitonen, P.H., Rowland, K.L., and Cmarik, J.L.:  Metabolism of doxylamine succinate in Fischer 344 rats, Part I:  distribution and excretion.  J. Analy. Tox. 10: 18-23, 1986. 
 

2. Inskeep, P.B., Koga, N., Cmarik, J.L., and Guengerich, F.P.:  Covalent binding of 1,2-dihaloalkanes to DNA and stability of the major DNA adduct, S-[2-(N⁷-guanyl)ethyl]glutathione. Cancer Res. 46: 2839-2844, 1986. 
 

3. Thompson, H.C., Jr., Holder, C.L., Siitonen, P.H., Rowland, K.L., Gosnell, A.B., and Cmarik, J.L.:  Metabolism of pyrilamine maleate in Fischer 344 rats, Part I: Activity excretion profiles. J. Analy. Tox. 11: 252-256, 1987. 
 

4. Humphreys, W.G., Kim, D.-H., Cmarik, J.L., Shimada, T., and Guengerich, F.P.:   Comparison of the DNA alkylating properties and mutagenic responses caused by a series of S-(2-haloethyl)-substituted cysteine and glutathione derivatives. Biochemistry 29: 10342-10350, 1990. 
 

5. Cmarik, J.L., Inskeep, P.B., Meyer, D.J., Meredith, M.J., Ketterer, B., and Guengerich, F.P.:  Selectivity of rat and human glutathione S-transferases in activation of ethylene dibromide by glutathione conjugation and DNA binding and induction of unscheduled DNA synthesis in human hepatocytes. Cancer Res. 50: 2747-2752, 1990. 
 

6. Bowling, J.M., Bruner, K.L., Cmarik, J.L., and Tibbetts, C.:  Neighboring nucleotide interactions during DNA sequencing gel electrophoresis. Nucleic Acids Res. 19: 3089-3097, 1991. 
 

7. Cmarik, J.L., Humphreys, W.G., Bruner, K.L, Lloyd, R.S., Tibetts, C., and Guengerich, F.P.:   Mutation spectrum and sequence alkylation selectivity resulting from modification of bacteriophage M13mp18 DNA with S-(2-chloroethyl) glutathione:  evidence for a role of S-[2-(N⁷-guanyl)ethyl] glutathione as a mutagenic lesion formed from ethylene dibromide.  J. Biol. Chem. 267: 6672-6679, 1992. 
 

8. Cmarik, J.L., Herschman, H., and Colburn, N.H.:  Preferential primary-response gene expression in promotion-resistant versus promotion-sensitive JB6 cells.  Mole. Carc. 11: 115-124, 1994. 
 

9. Dong, Z., Cmarik, J.L., Wendel, E.J., and Colburn, N.H.:  Differential transformation efficiency but not AP-1 induction under anchorage-dependent and -independent conditions. Carcinogenesis 15: 1001-1004, 1994. 
 

10. Cmarik, J.L., Li, Y., Ogram, S.A., Min, H., Reeves, R., and Colburn, N.H.:  Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells. Oncogene 16: 3387-3396, 1998. 
 

11. Cmarik, J.L., Min, H., Hegamyer, G., Zhan, S., Kulesz-Martin, M., Yoshinaga, H., Matsuhashi, S., and Colburn, N.H.:  Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc. Natl. Acad. Scis. USA 96: 14037-14042, 1999. 
 

12 Cmarik, J.L., Hegamyer, G., Gerrard, B., Dean, M., and Colburn, N.H.:  cDNA cloning and mapping of mouse pleckstrin (Plek), a gene upregulated in transformation-resistant cells.  Genomics 66: 204-212, 2000. 
 

13. Yang, H.S., Jansen, A.P., Nair, R., Shibahara, K., Verma, A.K., Cmarik, J.L., and Colburn, N.H.:  A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation.  Oncogene 20: 669-676, 2001. 
 

14. Nishigaki, K., Thompson, D., Yugawa, T., Rulli, K., Hanson, C., Cmarik, J., Gutkind, J.S., Teramoto, H., and Ruscetti, S.:  Identification and characterization of a novel Ste20/germinal center kinase-related kinase, polyploidy-associated protein kinase. J. Biol. Chem. 278: 13520-13530, 2003. 
 

Manuscripts Submitted: 
 

15. Yugawa, T., Nishigaki, K., Cmarik, J., Hanson, C., Thompson, D., and Ruscetti, S.:  Involvement of apoptosis-related molecules in the induction of Epo-independent proliferation of erythroid cells infected with the Friend spleen focus-forming virus.  Submitted, 2005. 
 

Book Chapters, Invited Submissions, and Published Proceedings of Symposia: 
 

1. Cmarik, J.L., and Owen, D.A.:  Models for highly phenylated trasition metal-containing polymers; derivatives of the pentaphenylcylclopentadienyl ligand. Proc. A.C.S. Div. Polymeric Materials Sci. and Eng. 49: 353-357, 1983. 
 

2. Inskeep, P.B., Koga, N., Cmarik, J.L., Peterson, L.A., and Guengerich, F.P.:  Structural and Chemical characterization of S-[2-(N⁷-guanyl)ethyl]glutathione, the major DNA adduct formed from 1,2-dibromoethane. Fed. Proc. 45: 1626, 1986. 
 

3. Guengerich, F.P., Cmarik, J.L., Peterson, L.A., Koga, N., and Inskeep, P.B.:  Glutathione-mediated formation of vic-dihaloalkane/DNA adducts.  In Glutathione S-Transferases and Carcinogenesis (Mantle, T.J., Pickett, C.B., and Hayes, J.D., eds.), Taylor and Francis, London, pp. 189-197, 1987.. 
 

4. Guengerich, F.P., Peterson, L.A., Cmarik, J.L., Koga, N., and Inskeep, P.B.:  Activation of dihaloalkanes by glutathione conjugation and formation of DNA adducts.  Env. Health Perspectives 76: 15-18, 1987. 
 

5. Guengerich, F.P., Humphreys, W.G., Kim, D.-H., Oida, T., and Cmarik, J.L.:  DNA-glutathione adducts derived from vic-dihaloalkanes: mechanisms of mutagenesis.  In Xenobiotics and Cancer (Ernster, L., et al., eds.) Japan Scientific Society Press, Tokyo, Japan/Taylor and Francis, Ltd., London, England, pp. 101-107, 1991. 
 

6. Guengerich, F.P., Min, K.-S., Persmark, M., Kim, M.-S., Humphreys, W.G., Cmarik, J., and Thier, R.:  Dihaloalkanes and polyhaloalkanes. In DNA Adducts: Identification and Biological Significance (Hemminki,K., et al., eds.) International Agency for Research on Cancer, Lyon, France, pp. 57-72, 1994. 
 

7. Cmarik, J.L., and Colburn, N.H.:  Use of mouse JB6 cells to identify molecular targets and novel agents for prevention of carcinogenesis.  In Food Factors for Cancer Prevention (Ohigashi, H., et al., eds.) Springer-Verlag, Tokyo, Japan, pp. 67-76, 1997. 
 

8. Hsu, T.-C., Young, M., Cmarik, J.L., and Colburn, N.:  Activator Protein-1 (AP-1) and NF-κB dependent transcriptional events in carcinogenesis.  In Signal Transduction by Oxidant Stresses, Free Radical Biology & Medicine 28: 1338-1348, 2000. 
 

9. Dong, Z. and Cmarik, J.L.:  Harvesting Cells under Anchorage-Independent Cell Transformation Conditions for Biochemical Analyses.  Science STKE 2002: PL7, 2002. 
 
 

Abstracts: 
 

1. Cmarik, J.L., Inskeep, P.B., Meyer, D.J., Coles, B., Meredith, M.J., Ketterer, B., and Guengerich, F.P.:  Activation of ethylene dibromide by glutathione conjugation: selectivity of rat and human glutathione S-transferases and DNA binding and induction of unscheduled DNA synthesis in human hepatocytes. Gordon Research Conference on Drug Metabolism, Plymouth, New Hampshire, 18-24 July, 1988. 
 

2. Cmarik, J.L., Inskeep, P.B., Meredith, M.J., Meyer, D.J., Ketterer, B., and Guengerich, F.P.:  Activation of ethylene dibromide by glutathione conjugation in rat and human systems. Brookhaven Symposium on DNA Damage and Repair in Human Tissues, Upton, Long Island, New York, 1-4 October, 1989. 
 

3. Cmarik, J.L., Lloyd, R.S., Bruner, K.L., Tibbetts, C., and Guengerich, F.P.:  Mutational spectrum resulting from DNA adducts of 1,2-dibromoethane. Proc. Amer. Assoc. Cancer Res. 32: 102., 1991. 
 

4.  Cmarik, J.L. and Colburn, N.H.:  Differential induction of TIS (TPA-inducible sequence) mRNAs by TPA in transformation-responsive and resistant JB6 cell lines. Proc. Amer. Assoc. Cancer Res. 34: 510, 1993. 
 

5.  Cmarik, J.L., Herschman, H., and Colburn, N.H.:  The TIS1 and TIS21 primary response genes are candidate tumor promotion suppressor genes. J. Cell. Biochem., Keystone Symposia on Molecular & Cellular Biology Supplement 18C: 187, 1994. 
 

6.  Cmarik, J.L., Hegamyer, G., and Colburn, N.H.:  Candidate mediators or inhibitors of neoplastic transformation identified by mRNA differential display.  Proceedings of the American Association for Cancer Research 37:518, 1996. 
 

7. Cmarik, J.L., Li, Y., Ogram, S.A., Min, H., Reeves, R., and Colburn, N.H.:  High mobility group HMG-Y protein is induced by tumor promoter in transformation-sensitive but not -resistant cells.  Proc. Amer. Assoc. Cancer Res. 39:450, 1998. 
 

8. Cmarik, J.L., Hegamyer, G., and Colburn, N.H.:  Novel molecular targets for cancer prevention identified by mRNA differential display. First Ann. Mtg. on the Exp. Thera.of Human Cancer, Frederick, Maryland, 11-13 June, 1998. 
 

9. Cmarik, J.L., Min, H., Hegamyer, G., and Colburn, N.H.:  Novel differentially expressed protein inhibits tumor promoter-induced neoplastic transformation.  15th Ann. Mtg. on Oncogenes and Tumor Suppressors, Frederick, MD, 22-27 June, 1999. 
 

10. Rulli, K., Yugawa, T., Nishigaki, K., Hanson, C., Cmarik, J., and Ruscetti, S.:  Ex vivo and in vivo biological effects of a truncated form of the receptor tyrosine kinase STK activated by interaction with the SFFV envelope glycoprotein or by point mutation.  15th Intl. Workshop on Retroviral Pathogenesis, Glasgow, Scotland, 17-21 September, 2003. 
 

11. Yiannoulos, G., Cmarik, J., Ruscetti, S.K., Hoffman, P.M., and Wilt, S.G.: Minocycline delays disease onset and microglial activation in a rat retroviral neuroinflammatory disease.  Society for Neuroscience Ann. Mtg., New Orleans, Louisiana, 8-12 November, 2003.  
 

12. Cmarik, J., MacPherson, G., Hanson, C., and Ruscetti, S.:  Neurological Disease Induced by Murine Leukemia Virus PVC-211.  First Annual CCR Staff Scientist and Staff Clinician Retreat, Rockville, Maryland, 25 April, 2005.